Canditral Patient Counseling Information

Information for Patients: The topical effects of mucosal exposure may be different between the ITRACONAZOLE Capsules and Oral Solution. Only the Oral Solution has been demonstrated effective for oral and/or esophageal candidiasis. ITRACONAZOLE Capsules should not be used interchangeably with ITRACONAZOLE Oral Solution.
Instruct patients to take ITRACONAZOLE Capsules with a full meal. ITRACONAZOLE Capsules must be swallowed whole.
Instruct patients about the signs and symptoms of congestive heart failure, and if these signs or symptoms occur during ITRACONAZOLE administration, they should discontinue ITRACONAZOLE and contact their healthcare provider immediately.
Instruct patients to stop ITRACONAZOLE treatment immediately and contact their healthcare provider if any signs and symptoms suggestive of liver dysfunction develop. Such signs and symptoms may include unusual fatigue, anorexia, nausea and/or vomiting, jaundice, dark urine, or pale stools.
Instruct patients to contact their physician before taking any concomitant medications with itraconazole to ensure there are no potential drug interactions.
Instruct patients that hearing loss can occur with the use of itraconazole. The hearing loss usually resolves when treatment is stopped, but can persist in some patients. Advise patients to discontinue therapy and inform their physicians if any hearing loss symptoms occur.
Instruct patients that dizziness or blurred/double vision can sometimes occur with itraconazole. Advise patients that if they experience these events, they should not drive or use machines.